News

CARB-X News

  • 06.17.2019  |  CARB-X awards Oxford Drug Design funding to develop a new class of antibiotics to treat drug-resistant Gram-negative infections

    CARB-X is awarding Oxford Drug Design Ltd. of Oxford, UK, up to $2.55 million in non-dilutive funding with the possibility of $4.24 million more if certain project milestones are met, to develop a new class of antibiotics for the treatment of Gram-negative bacterial infections using an approach designed to reduce the likelihood that resistance will emerge.

    Full Story

  • 05.14.2019  |  CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii

    CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species. This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.

    Full Story

  • 04.30.2019  |  CARB-X launches new Funding Rounds to support the development of antibiotics, vaccines, diagnostics and other life-saving products that target drug-resistant bacteria

    CARB-X announced today its 2019 rounds of funding to support the development of antibiotics, vaccines, biotherapeutics, diagnostics and other life-saving products to address the rising threat of drug-resistant bacteria. There are four funding rounds representing CARB-X’s most ambitious call for proposals from product developers seeking financial, scientific and business support to accelerate the development of innovative products targeting the most dangerous superbugs.

    Full Story

  • 03.14.2019  |  Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs

    CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria. Under the agreement, BMBF will also provide an additional €1 million in direct support to a consortium of the German Center for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects. CARB-X is a global non-profit partnership housed at Boston University.

    Full Story

  • 03.04.2019  |  CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs

    CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens. This is ContraFect’s second antibacterial project to earn CARB-X funding.

    Full Story

  • 02.25.2019  |  CARB-X expands its Global Accelerator Network to support the development of antibiotics, rapid diagnostics, vaccines and other life-saving products to combat drug-resistant superbugs

    CARB-X is expanding its Global Accelerator Network, bringing together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The new accelerators join CARB-X’s existing accelerator partners – CLSI, MassBio and RTI International in the United States and the Wellcome Trust in the United Kingdom.

    Full Story

  • 02.06.2019  |  CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs

    CARB-X is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to treat serious infections caused by Gram-negative bacteria.

    Full Story

  • 02.04.2019  |  CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs

    CARB-X is awarding Polyphor (SIX: POLN) of Allschwil, Switzerland, up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.

    Full Story

  • 01.03.2019  |  CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa

    CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support

    Full Story